Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay

Transplantation

Volumn 82, Issue 5, 2006, Pages 663-668

  Kowalski, Richard J ^a   Post, Diane R ^a   Mannon, Roslyn B ^b   Sebastian, Anthony ^c   Wright, Harlan I ^c   Sigle, Gary ^c   Burdick, James ^d   Elmagd, Kareem Abu ^e   Zeevi, Adriana ^e   Lopez Cepero, Mayra ^f   Daller, John A ^g   Gritsch, H Albin ^h   Reed, Elaine F ^h   Jonsson, Johann ⁱ   Hawkins, Douglas ^j   Britz, Judith A ^a  

^a Cylex Incorporated   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f LifeLink Foundation   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Inova Hospital for Children   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

CD4; Immune function; Infection; Rejection; Relative risk

Indexed keywords

ADENOSINE TRIPHOSPHATE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BACTERIAL INFECTION; BIOPSY; BLOOD SAMPLING; CALCULATION; CARDIAC GRAFT REJECTION; CARDITIS; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE COURSE; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HEPATITIS; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INTESTINE INFECTION; INTESTINE TRANSPLANTATION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY INFECTION; KIDNEY PANCREAS TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; META ANALYSIS; MYCOSIS; ORGAN TRANSPLANTATION; PATIENT CARE; POSTOPERATIVE PERIOD; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; UNITED STATES; VIRUS INFECTION;

GRAFT REJECTION; HUMANS; INFECTION; ODDS RATIO; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK;

EID: 33748690103     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000234837.02126.70     Document Type: Article

References (18)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1998 to 1996. N Engl J Med 2000; 342(9): 605.
2. Shapiro R, Young J, Milford E, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5(4 pt 2): 874.
3. Burdick JF, Shinozuka N. Immune Monitoring for Transplant Recipients. In: Rackesen LC, Solez T, Burdick JF (eds). Kidney Transplant Rejection, 3rd Ed. New York: Marcel Dekker, 1998: 564.
4. Hricik DE, Heeger PS. Minimization of Immunosuppression in Kidney Transplantation. Transplantation 2001; 72(8): S32.
5. U.S.D.H.H.S. Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays; Draft Guidance for Industry and FDA. February 21, 2002. U.S.D.H.H.S., FDA, Division of Clinical Laboratory Devices. 1.
6. Regev A, Molina E, Moura R, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10(10): 1233.
7. Marboe C, Billingham M, Eisen H, et al. Nodular endocardial infiltrates (Quilty Lesions) cause significant variability in diagnosis of ISHTL Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 2005; 24(7s): S219.
8. McTaggart R, Terrault N, Vardanian A, et al. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation. Liver Transpl 2004; 10(8): 975.
9. Fishbein M, Kogashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol 2004; 19(2): 166.
10. United States Department of Health and Human Services. K013169; Cylex Immune Cell Function Assay, April 02, 2002.
11. Kowalski R, Post D, Schneider MC, et al. Immune Function Testing: An Adjunct to Therapeutic Drug Monitoring in Transplant Patient Management. Clin Transplant 2003; 17: 77.
12. Buttgereit F, Burmester G-R, Brand MD. Bioenergetics of Immune Functions: Fundamental and Therapeutic Aspects. Immunol Today 2000; 21: 192.
13. Moore DS, McCabe GP. Introduction to the Practice of Statistics. New York: Freeman, 2003.
14. Zeevi A, Britz JA, Bentlejewski C, et al. Monitoring Immune Function during Tacrolimus Weaning in Small Bowel Transplant Recipients. Transpl Imm 2005; 15: 17.
15. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004; 4(3): 384.
16. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6(2): 262.
17. Lachenbruch PA, Rosenberg AS, Bonvini E, et al. Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. Am J Transplant 2004; 4(4): 451.
18. Nankivell BJ, Borrows RJ, Fung SL.-S, et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78(2): 242.